预约演示

AstraZeneca/Sanofi’s RSV treatment shown to reduce hospitalisations in infants

2024-01-09

临床结果上市批准临床研究

AstraZeneca and Sanofi’s Beyfortus (nirsevimab) showed positive results in their HARMONIE trial, demonstrating that the respiratory syncytial virus (RSV) injection could significantly reduce infant hospitalisations.

AstraZenecaas coSanofiy tBeyfortussinirsevimabl Southampton, the University of Southampton, St George’s University Hospital and the University of Nottingham, with support from the National Institute for Health and Care Research (NIHR).

Responsible for more than 30University Hospital SouthamptonalisatUniversity of Southampton cSt George’s University Hospitalually cauUniversity of Nottinghamtoms.National Institute for Health and Care Research (NIHR)

However, for some infants, it can cause more severe lung problems, including bronchiolitis and pneumonia.cold-like symptoms

Involving 8,058 infants under the age of 12 months from the UK, France and Gebronchiolitisre eipneumoniar approaching their first RSV season, results from the trial showed that a single dose of Beyfortus offered immediate protection against RSV.

Beyfortus, a human monoclonal antibody that is designed to bind to the fusion protein on the surface of the RSV virus, has already received approval from the European Commission and the US Food BeyfortusAdministration to treat newborns and iRSVnts during their first RSV season.

Beyfortus037 infants who were randomly assigned to receive the antibody injection, the efficacy of Beyfortus against hospitalisation for RSV-associated lower respiratory tract infection wasFood and Drug Administrationermany and 83.4% in the UK, with minimal adverse events, in comparison to infants who received no RSV intervention.

Professor Saul Faust, co-study leader and director of NIHR Southampton Clinical Research Facility, Beyfortusese latest results show that RSV-associated lower respiratory tract infectionect thousands of babies from hospitalisation when used in conditions similar to routine clinical practice.”

Dr Simon Royal, NIHR national specialty lead, primary NIHR and honorary assistant professor, University of Nottingham Medical School, said: “This study has shown how primary care clinicians, hospital specialists and the whole UK NIHR system can work together in a new partnership with industry to deliver rapid data to support a critical NHS need.”

Usually occurring from October, peaking in December, until March, the antibody injection could ease the strain that RSV typically causes on NHS resources during the winter season, in both secondary and primary care.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构